STAAR Surgical Company
Financials
Valuation Metrics
STAAR Surgical Company's Market Cap is $1.24B. At end of 2025 it was $1.14B. Ranked #2297 of 3,118 in US market (top 74%), #923 of 1,474 on NASDAQ (top 63%), #146 of 203 in Health Care Equipment & Services (top 72%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $1.24B | US#2,297/3,118 Sec#146/203 |
| Revenue | $340M | US#2,378/3,118 Sec#152/203 |
| Net Income | $4M | US#2,203/3,118 Sec#120/203 |
| Total Assets | $475M | US#2,778/3,118 Sec#162/203 |
| Net Assets | $365M | US#2,419/3,118 Sec#135/203 |
| Employees | 921 | US#2,010/3,118 Sec#138/203 |
| Value | ||
| P/E | 323.45x | US#2,191/3,118 Sec#119/203 |
| P/B | 3.40x | US#1,897/3,118 Sec#104/203 |
| P/S | 3.66x | US#1,965/3,118 Sec#130/203 |
| EV/EBITDA | 35.23x | US#2,276/3,118 Sec#121/203 |
| FCF Yield | -0.54% | US—/3,118 Sec—/203 |
| Profitability | ||
| ROE | 1.05% | US#2,085/3,118 Sec#114/203 |
| ROA | 0.81% | US#2,049/3,118 Sec#117/203 |
| Op. Margin | 10.32% | US#1,549/3,118 Sec#74/203 |
| Revenue Growth | 51.30% | US#217/3,118 Sec#10/203 |
| Financial Health | ||
| Debt Ratio | 30.05% | US#339/3,118 Sec#36/203 |
| Total Debt | $36M | US#2,657/3,118 Sec#159/203 |
| FCF | $-7M | US#2,344/3,118 Sec#150/203 |
| Cash | $149M | US#1,955/3,118 Sec#122/203 |
| Current Ratio | 4.66x | US#502/3,118 Sec#41/203 |
| Net Debt/EBITDA | -3.51x | US#96/3,118 Sec#10/203 |
| Dividend | ||
| Div. Yield | 0.00% | US—/3,118 Sec—/203 |
| Payout Ratio | 0.00% | US—/3,118 Sec—/203 |
| Performance | ||
| 1Y Return | -3.59% | US#2,052/3,118 Sec#144/203 |
| 1M Return | 10.99% | US#895/3,118 Sec#75/203 |
| From 52W High | -30.47% | US#2,013/3,118 Sec#152/203 |
| 1Y MDD | -42.77% | US#2,064/3,118 Sec#133/203 |
| Trading | ||
| Volume | 613,978 shares | US#2,162/3,118 Sec#152/203 |
| Trading Value | $15M | US#2,255/3,118 Sec#149/203 |
| Per Share | ||
| EPS | $0.08 | US#2,092/3,118 Sec#118/203 |
| BPS | $7.34 | US#2,049/3,118 Sec#122/203 |
Company Info
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, and sells phakic implantable lenses for the eye and accessory delivery systems to deliver the lenses into the eye. The company offers implantable collamer lens product family (ICLs) comprising EVO ICL, EVO+ ICL, EVO Visian ICL, and EVO Viva ICL for use in refractive surgery for the treatment of visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia. It serves health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as ophthalmologists. The company sells its products directly through its sales representatives in Japan, the United States, Germany, Spain, Singapore, Canada, and the United Kingdom, as well as through representatives and independent distributors in China, Korea, India, France, Benelux, Italy, and internationally. STAAR Surgical Company was incorporated in 1982 and is headquartered in Lake Forest, California.